CN103877411A - Medicinal composition for preventing and treating myocardial fibrosis and application thereof - Google Patents
Medicinal composition for preventing and treating myocardial fibrosis and application thereof Download PDFInfo
- Publication number
- CN103877411A CN103877411A CN201410072891.1A CN201410072891A CN103877411A CN 103877411 A CN103877411 A CN 103877411A CN 201410072891 A CN201410072891 A CN 201410072891A CN 103877411 A CN103877411 A CN 103877411A
- Authority
- CN
- China
- Prior art keywords
- parts
- myocardial fibrosis
- pharmaceutical composition
- semen
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
The invention discloses a medicinal composition for preventing and treating myocardial fibrosis and an application thereof. The medicinal composition for preventing and treating myocardial fibrosis is prepared from the following traditional Chinese medicinal materials in parts by weight: 42-60 parts of peanut shell, 20-34 parts of rhodiola rosea, 20-34 parts of platycladi seed, 15-25 parts of herba epimedii, 15-25 parts of lindernia ruellioides, 18-26 parts of large leaf moss, 11-20 parts of lotus leaf, 42-60 parts of vigna umbellata, 10-20 parts of corn stigma and 8-16 parts of liquorice. The medicinal composition has the advantage of obvious effect on prevention of myocardial fibrosis disease; meanwhile, cost for controlling is reduced, and drug dependency of patients is high.
Description
Technical field
The invention belongs to Chinese medicine technical field, in particular to a kind of pharmaceutical composition and application thereof that prevents and treats myocardial fibrosis.
Background technology
In recent years, people have recognized that multiple cardiovascular disease is as myocardial infarction, chronic heart failure, atrial fibrillation, hypertension heart damage, Diabetic cardiomyopathy, cardiomyopathy and myocarditis etc. gradually, all with the pathological process of myocardial remodelling, and myocardial fibrosis is the important step of myocardial remodelling, therefore prevention and control heart interstitial collagen hypertrophy is the important step of myocardial fibrosis treatment.
Summary of the invention
The object of the present invention is to provide a kind of pharmaceutical composition and application that prevents and treats myocardial fibrosis.This pharmaceutical composition is as secret prescription handed down in the family from generation to generation, and it is remarkable in the prevention effect for myocardial fibrosis, and has advantages of that cost is low, determines that it is a kind of specific medicament of preventing and treating myocardial fibrosis disease after clinical application for many years.
The object of the present invention is achieved like this:
Prevent and treat a pharmaceutical composition for myocardial fibrosis, it is prepared from by the traditional Chinese medicinal material raw materials that comprises following weight portion: Pericarppium arachidis hypogaeae 42-60 part, Radix Rhodiolae 20-34 part, Semen Platycladi 20-34 part, Herba Epimedii 15-25 part, Lindernia ruellioides (Colsm.) Pennell 15-25 part, Rhodobryum roseum Limpr. 18-26 part, Folium Nelumbinis 11-20 part, Semen Phaseoli 42-60 part, Stigma Maydis 10-20 part, Radix Glycyrrhizae 8-16 part.
Preferably, the pharmaceutical composition of control myocardial fibrosis as above, it is prepared from by the traditional Chinese medicinal material raw materials of following weight portion: Pericarppium arachidis hypogaeae 42-60 part, Radix Rhodiolae 20-34 part, Semen Platycladi 20-34 part, Herba Epimedii 15-25 part, Lindernia ruellioides (Colsm.) Pennell 15-25 part, Rhodobryum roseum Limpr. 18-26 part, Folium Nelumbinis 11-20 part, Semen Phaseoli 42-60 part, Stigma Maydis 10-20 part, Radix Glycyrrhizae 8-16 part.
In a most preferred embodiment of the present invention, the pharmaceutical composition of control myocardial fibrosis as above is prepared from by the traditional Chinese medicinal material raw materials of following weight portion: 50 parts of Pericarppium arachidis hypogaeaes, 26 parts of Radix Rhodiolaes, 26 parts of Semen Platycladi, 20 parts of Herba Epimedii, 20 parts of Lindernia ruellioides (Colsm.) Pennell, 22 parts of Rhodobryum roseum Limpr.s, 15 parts, Folium Nelumbinis, 50 parts of Semen Phaseolis, 14 parts of Stigma Maydis, 11 parts, Radix Glycyrrhizae.
Find by a large amount of animal experiment research, pharmaceutical composition of the present invention is for the prevention effect highly significant of Rat Myocardial Fibrosis model, therefore, second object of the present invention is to provide a kind of pharmaceutical applications, i.e. the application of aforementioned pharmaceutical compositions in the medicine of preparation control myocardial fibrosis.In pharmaceutical applications, this pharmaceutical composition can be prepared as oral formulations: oral formulations wherein comprises oral liquid, tablet, capsule, granule.
Compared with prior art, the pharmaceutical composition tool the present invention relates to has the following advantages and marked improvement:
(1) effect of prevention myocardial fibrosis is remarkable: find by zoopery, type i collagen content in the serum of the Chinese drug-treated group of gavage medicinal liquid of the present invention, the content of cardiac muscular tissue's hydroxyproline, left ventricle index has all obtained significant reduction, there is significant difference (P < 0.05) or utmost point significant difference (P < 0.01) compared with model control group, this illustrates that Chinese medicine composition of the present invention can be by suppressing the synthetic increase of type i collagen of isoproterenol induction, thereby suppress the formation and development of Rat Myocardial Fibrosis.
(2) cost is few, easy to use: this pharmaceutical composition is prepared from by some conventional traditional Chinese medicinal material raw materials, and oral, therefore cost accounting is low, and patient not only spends few, and medication interdependence is high.
The specific embodiment
Be below specific embodiments of the invention, technical scheme of the present invention is done to further description, but protection scope of the present invention is not limited to these embodiment.Every do not deviate from the change of the present invention design or be equal to substitute include within protection scope of the present invention.，
It should be noted that, the traditional Chinese medicinal material raw materials that the embodiment of the present invention adopts has following source: Pericarppium arachidis hypogaeae is selected the pod shell of pulse family Arachis plant Semen arachidis hypogaeae Arachis hypogaea L. fruit.Radix Rhodiolae is selected dry root and the rhizome of crassulaceae plants Radix Rhodiolae.Semen Platycladi is selected the kernel of Cupressaceae plant Cacumen Platycladi Biotaorientalis (L.) Endl..Herba Epimedii is selected the dried leaves of Berberidaceae plant Herba Epimedii (Epimedium brevicornum Maxim.).Lindernia ruellioides (Colsm.) Pennell is selected the dry herb of goatweed Lindernia ruellioides (Colsm.) Pennell Lindemia ruellioides (Colsm) Pennell..Rhodobryum roseum Limpr. is selected the dry herb of warm ground of moss Bryaceae rhodobryum spp plant great Ye moss Rhodobryum giganteum (Schwaegr.) Par.Folium Nelumbinis is selected the dried leaves of nymphaeaceae plant lotus Nelumbo nuciferaGaertn..Semen Phaseoli is selected the dry mature seed of leguminous plant Semen Phaseoli Phaseolus calcaratus Roxb..Stigma Maydis is selected style and the stigma of grass Semen Maydis ZeamaysL..Radix Glycyrrhizae is selected the dry root and rhizome into dicotyledon pulse family Leguminosae Radix Glycyrrhizae Glycyrrhiza uralensis Fisch..
Embodiment 1
Crude drug prescription: Pericarppium arachidis hypogaeae 5.0kg, the large 2.6kg of red scape, Semen Platycladi 2.6kg, Herba Epimedii 2.0kg, Lindernia ruellioides (Colsm.) Pennell 2.0kg, Rhodobryum roseum Limpr. 2.2kg, Folium Nelumbinis 1.5kg, Semen Phaseoli 5.0kg, Stigma Maydis 1.4kg, Radix Glycyrrhizae 1.1kg.
Preparation method: take Pericarppium arachidis hypogaeae, Radix Rhodiolae, Semen Platycladi, Herba Epimedii, Lindernia ruellioides (Colsm.) Pennell, Rhodobryum roseum Limpr., Folium Nelumbinis, Semen Phaseoli, Stigma Maydis and the Radix Glycyrrhizae of recipe quantity, clean roguing, dry, pulverize; Again above-mentioned graininess medical material is added water and covers powder 2cm, soak 1-1.2h, pull medical material out and put multi-functional extraction and decoct with water secondary in filling with, add up for the first time the water of 10 times of amounts of medical material, decoct 2h, get decocting liquid, filter, add up for the second time the water of 8 times of amounts of medical material, decoct 1h, get twice decocting liquid and merge, filter the concentrated solution that while being concentrated into 90 ℃, relative density is 1.15g/mL; Concentrated solution is set to 0 to-5 ℃ of deepfreeze 24h, cold preservation liquid is added to 0.3% filter aid kieselguhr, filter, filtrate reconcentration containing 8g crude drug amount, sets to 0-5 ℃ of deepfreeze 24h to every milliliter, and cold preservation liquid is filtered, and obtains medicinal liquid.
Embodiment 2
Crude drug prescription: Pericarppium arachidis hypogaeae 5.2kg, Radix Rhodiolae 2.0kg, Semen Platycladi 2.5kg, Herba Epimedii 2.5kg, Lindernia ruellioides (Colsm.) Pennell 2.0kg, Rhodobryum roseum Limpr. 2.6kg, Folium Nelumbinis 1.8kg, Semen Phaseoli 6.0kg, Stigma Maydis 1.8kg, Radix Glycyrrhizae 1.5kg.
Preparation method: take Pericarppium arachidis hypogaeae, Radix Rhodiolae, Semen Platycladi, Herba Epimedii, Lindernia ruellioides (Colsm.) Pennell, Rhodobryum roseum Limpr., Folium Nelumbinis, Semen Phaseoli, Stigma Maydis and the Radix Glycyrrhizae of recipe quantity, clean roguing, dry, pulverize; Again above-mentioned graininess medical material is added water and covers powder 2cm, soak 1-1.2h, pull medical material out and put multi-functional extraction and decoct with water secondary in filling with, add up for the first time the water of 8 times of amounts of medical material, decoct 2h, get decocting liquid, filter, add up for the second time the water of 8 times of amounts of medical material, decoct 1h, get twice decocting liquid and merge, filter the concentrated solution that while being concentrated into 90 ℃, relative density is 1.15g/mL; Concentrated solution is set to 0 to-5 ℃ of deepfreeze 24h, cold preservation liquid is added to 0.3% filter aid kieselguhr, filter, filtrate reconcentration containing 8g crude drug amount, sets to 0-5 ℃ of deepfreeze 24h to every milliliter, and cold preservation liquid is filtered, and obtains medicinal liquid.
Embodiment 3
Crude drug prescription: Pericarppium arachidis hypogaeae 4.6kg, Radix Rhodiolae 3.3kg, Semen Platycladi 3.0kg, Herba Epimedii 1.5kg, Lindernia ruellioides (Colsm.) Pennell 2.5kg, Rhodobryum roseum Limpr. 2.0kg, Folium Nelumbinis 1.1kg, Semen Phaseoli 5.0kg, Stigma Maydis 1.0kg, Radix Glycyrrhizae 1.2kg.
Preparation method: take Pericarppium arachidis hypogaeae, Radix Rhodiolae, Semen Platycladi, Herba Epimedii, Lindernia ruellioides (Colsm.) Pennell, Rhodobryum roseum Limpr., Folium Nelumbinis, Semen Phaseoli, Stigma Maydis and the Radix Glycyrrhizae of recipe quantity, clean roguing, dry, pulverize; Again above-mentioned graininess medical material is added water and covers powder 2cm, soak 1-1.2h, pull medical material out and put multi-functional extraction and decoct with water secondary in filling with, add up for the first time the water of 8 times of amounts of medical material, decoct 2h, get decocting liquid, filter, add up for the second time the water of 6 times of amounts of medical material, decoct 1h, get twice decocting liquid and merge, filter the concentrated solution that while being concentrated into 90 ℃, relative density is 1.15g/mL; Concentrated solution is set to 0 to-5 ℃ of deepfreeze 24h, cold preservation liquid is added to 0.3% filter aid kieselguhr, filter, filtrate reconcentration containing 9g crude drug amount, sets to 0-5 ℃ of deepfreeze 24h to every milliliter, and cold preservation liquid is filtered, and obtains about liquid.
The effectiveness study of embodiment 4 medicinal liquid control of the present invention myocardial fibrosis
36 of Wistar rats, female half and half, body weight 180-220g, is divided into following three groups at random: normal group, model group, Chinese drug-treated group, 12 every group.Except normal group, all the other two groups equal back subcutaneous injection isoproterenol 5mg/ (kgd), 7d continuously, Chinese drug-treated group rat started medicinal liquid 14d prepared by the gastric infusion embodiment of the present invention 1 from the 2nd day, every day each 1 time sooner or later, each gavage dosage is 10mL/kg, and normal group and model group give the purified water of same volume every day.
After last administration, water 24h is can't help in fasting, rat weigh after 10% chloral hydrate (0.3mL/kg) anesthesia, abdominal aortic blood, get serum for subsequent use, open breast and take out heart, remove trunk and visceral pericardium fatty tissue, clean with normal saline, blot rear title left ventricular mass, calculate left ventricular mass index (left ventricular mass/body weight).Get serum, according to the explanation of ELISA test kit, measure the content of type i collagen in serum by microplate reader.In addition, heart tissue, with after ice normal saline flushing, is got 150mg myocardium of left ventricle tissue alkali hydrolysis method, uses the content of spectrophotometry cardiac muscular tissue hydroxyproline according to test kit explanation at 550nm wavelength place.The testing result of above index is referring to table 1.
Isoproterenol is β1receptor agonist, and existing great mass of data shows, continuous application isoproterenol can cause the generation of Rat Myocardial Fibrosis, and its main mechanism is the Angll concentration that has increased blood circulation and regional myocardial.The features such as this model is simple owing to having, expense is cheap, stable and durable effect, have become the common method of studying myocardial fibrosis.Result of the test by table 1 can find out, in model group serum, the content of type i collagen content, cardiac muscular tissue's hydroxyproline and left ventricle index are apparently higher than matched group (P<0.05 or P < 0.01).The present invention adopts Induced By Isoprenaline Rat Myocardial Fibrosis model, shows as left room index and raises, and left ventricle hydroxyproline content increases, and type i collagen increased content in serum shows the establishment of myocardial fibrosis model.
And the content of type i collagen content, cardiac muscular tissue's hydroxyproline, left ventricle index have all obtained significant reduction in the serum of the Chinese drug-treated group of gavage medicinal liquid of the present invention, there is significant difference (P<0.05) or utmost point significant difference (P < 0.01) compared with model control group, this explanation, the synthetic increase of type i collagen that Chinese medicine composition of the present invention can be induced by suppressing isoproterenol, thereby the formation and development of inhibition Rat Myocardial Fibrosis.
The indices impact of table 1 Chinese medicine on myocardial fibrosis rat
With normal group comparison,
＄p < 0.05,
＄ ＄p < 0.01;
With model group comparison,
★p < 0.05,
★ ★p < 0.01.
Claims (6)
1. a pharmaceutical composition of preventing and treating myocardial fibrosis, is characterized in that: described pharmaceutical composition is prepared from by the traditional Chinese medicinal material raw materials that comprises following weight portion: Pericarppium arachidis hypogaeae 42-60 part, Radix Rhodiolae 20-34 part, Semen Platycladi 20-34 part, Herba Epimedii 15-25 part, Lindernia ruellioides (Colsm.) Pennell 15-25 part, Rhodobryum roseum Limpr. 18-26 part, Folium Nelumbinis 11-20 part, Semen Phaseoli 42-60 part, Stigma Maydis 10-20 part, Radix Glycyrrhizae 8-16 part.
2. the pharmaceutical composition of control myocardial fibrosis according to claim 1, is characterized in that: described pharmaceutical composition is prepared from by the traditional Chinese medicinal material raw materials of following weight portion: Pericarppium arachidis hypogaeae 42-60 part, Radix Rhodiolae 20-34 part, Semen Platycladi 20-34 part, Herba Epimedii 15-25 part, Lindernia ruellioides (Colsm.) Pennell 15-25 part, Rhodobryum roseum Limpr. 18-26 part, Folium Nelumbinis 11-20 part, Semen Phaseoli 42-60 part, Stigma Maydis 10-20 part, Radix Glycyrrhizae 8-16 part.
3. the pharmaceutical composition of control myocardial fibrosis according to claim 2, is characterized in that: described pharmaceutical composition is prepared from by the traditional Chinese medicinal material raw materials of following weight portion: 50 parts of Pericarppium arachidis hypogaeaes, 26 parts of Radix Rhodiolaes, 26 parts of Semen Platycladi, 20 parts of Herba Epimedii, Lindernia ruellioides (Colsm.) Pennell 20 22 parts of part, time heart leather, 15 parts, Folium Nelumbinis, 50 parts of Semen Phaseolis, 14 parts of Stigma Maydis, 11 parts, Radix Glycyrrhizae.
4. the application of the compositions described in claim 1-3 any one in the medicine of preparation control myocardial fibrosis.
5. according to the application of claim 4, it is characterized in that: described medicine is oral formulations.
6. according to the application of claim 5, it is characterized in that: described oral formulations comprises oral liquid, tablet, capsule, granule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410072891.1A CN103877411B (en) | 2014-03-03 | 2014-03-03 | A kind of pharmaceutical composition preventing and treating myocardial fibrosis and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410072891.1A CN103877411B (en) | 2014-03-03 | 2014-03-03 | A kind of pharmaceutical composition preventing and treating myocardial fibrosis and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103877411A true CN103877411A (en) | 2014-06-25 |
| CN103877411B CN103877411B (en) | 2016-11-23 |
Family
ID=50946747
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410072891.1A Active CN103877411B (en) | 2014-03-03 | 2014-03-03 | A kind of pharmaceutical composition preventing and treating myocardial fibrosis and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103877411B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105327172A (en) * | 2015-11-19 | 2016-02-17 | 王丽 | Myocardial hypertrophy resistant pharmaceutical composition as well as preparation method and application thereof |
| CN108969620A (en) * | 2018-09-19 | 2018-12-11 | 栾云鹏 | Have both drug and preparation method thereof that is anti-oxidant and inhibiting liver tissue fibrosis function |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090252796A1 (en) * | 2008-04-07 | 2009-10-08 | Mazed Mohammad A | Nutritional supplement for the prevention of cardiovascular disease, alzheimer's disease, diabetes, and regulation and reduction of blood sugar and insulin resistance |
| CN103120768A (en) * | 2011-11-21 | 2013-05-29 | 成都市湔江制药厂 | Medicament for treating vital myocarditis and cardiomyopathy |
-
2014
- 2014-03-03 CN CN201410072891.1A patent/CN103877411B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090252796A1 (en) * | 2008-04-07 | 2009-10-08 | Mazed Mohammad A | Nutritional supplement for the prevention of cardiovascular disease, alzheimer's disease, diabetes, and regulation and reduction of blood sugar and insulin resistance |
| CN103120768A (en) * | 2011-11-21 | 2013-05-29 | 成都市湔江制药厂 | Medicament for treating vital myocarditis and cardiomyopathy |
Non-Patent Citations (10)
| Title |
|---|
| 《健康大讲堂》编委会: "《《本草纲目》中的对症秘方》", 31 July 2013, 黑龙江科学技术出版社 * |
| 宋敬东: "《《本草纲目》中药蔬果养生速查全书》", 30 November 2013, 天津科学技术出版社 * |
| 曾海莲等: "活血宁心汤治疗缺血性心脏病42例", 《湖南中医杂志》 * |
| 李文瑞等: "《中药别名辞典》", 30 September 1994, 中国科学技术出版社 * |
| 杜华贞: "《病理学与病理生理学》", 31 August 2011, 第四军医大学出版社 * |
| 武谦虎: "《美容中药一本通》", 31 October 2013, 中国医药科技出版社 * |
| 殷子杰等: "中医抗心肌纤维化研究趋势的分析与探讨", 《心脑血管病防治》 * |
| 罗献瑞: "《实用中草药彩色图集第6册》", 30 October 2001, 广东世界图书出版有限公司 * |
| 蔡永敏等: "《最新中药药理与临床应用》", 31 January 1999, 华夏出版社 * |
| 邱保国等: "《简明中药临床实用手册》", 31 January 2012, 中原出版传媒集团 中原农民出版社 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105327172A (en) * | 2015-11-19 | 2016-02-17 | 王丽 | Myocardial hypertrophy resistant pharmaceutical composition as well as preparation method and application thereof |
| CN108969620A (en) * | 2018-09-19 | 2018-12-11 | 栾云鹏 | Have both drug and preparation method thereof that is anti-oxidant and inhibiting liver tissue fibrosis function |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103877411B (en) | 2016-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102258563B (en) | Anti-cancer medicinal composition and Chinese medicinal composition | |
| CN103070943B (en) | Traditional Chinese medicine for treating cardiovascular and cerebrovascular diseases and preparation method of traditional Chinese medicine | |
| CN103877411B (en) | A kind of pharmaceutical composition preventing and treating myocardial fibrosis and application thereof | |
| CN101849987A (en) | Preparation of Chinese angelica and astragalus root mixture ethanol extract and aqueous extract and application in intervening in pulmonary fibrosis | |
| CN101856466B (en) | Medicine preventing and treating hypertension and stroke and being prepared by dendrobium officinale flower and method | |
| CN108186794B (en) | Traditional Chinese medicine composition for treating lung cancer and preparation method and application thereof | |
| CN104784670A (en) | Pharmaceutical composition for treating myocarditis and preparation method of pharmaceutical composition | |
| CN110292607B (en) | Traditional Chinese medicine composition for treating hypertension complicated with left ventricular hypertrophy and preparation method thereof | |
| CN102120000B (en) | Composition of effective parts of traditional Chinese medicine preparation for resisting Coxsackie virus B and preparation method thereof | |
| CN102526631A (en) | Traditional Chinese medicine preparation, tablet and capsule for curing dilated cardiomyopathy and preparation method | |
| CN104524359B (en) | A kind of Chinese medicine composition, its preparation method and application | |
| CN104587214A (en) | Traditional Chinese medicine for preventing radiodermatitis caused by lung cancer radiotherapy | |
| CN103719873A (en) | Chinese yam spleen-strengthening porridge and preparation method thereof | |
| CN103505670A (en) | Traditional Chinese medicine composition for treating primary bronchus lung cancer | |
| CN116570702B (en) | Traditional Chinese medicine composition for resisting ejection fraction retention type heart failure and application thereof | |
| CN102526470B (en) | Medicinal composition for treating primary hypertension | |
| CN109091532B (en) | Application of Tongguan capsule in preparation of medicine for treating hypertension and heart failure | |
| CN103083597B (en) | Chronic bronchitis treatment drug composition and preparation method thereof | |
| CN108619372B (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating pulmonary heart disease | |
| CN102631487B (en) | Traditional Chinese medicine composition capable of improving immunity and resisting fatigue | |
| CN107596337B (en) | A kind of pharmaceutical composition for increasing short bowel syndrome Intestinal Mucosal Injury in Patients Undergoing absorption area | |
| CN104473957B (en) | A kind of Chinese medicine monomer compositions for blood fat reducing and preparation thereof | |
| CN105267767A (en) | Medicine compound preventing alcohol-induced kidney damage and application thereof | |
| CN104857422A (en) | Composition treating colorectal cancer and applications of medicines treating colorectal cancer | |
| CN102961680B (en) | Traditional Chinese medicine preparation for treating gallstone and cholecystitis and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20230118 Address after: 331200 Chengbei Industrial Park, Zhangshu City, Yichun City, Jiangxi Province Patentee after: JIANGXI TIANYUAN PHARMACEUTICAL CO.,LTD. Address before: No. 4 Jianmin Street, Jimo, Shandong 266000 Patentee before: Liu Mei |